Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

2.06EUR
14 Jun 2019
Change (% chg)

€-0.02 (-0.77%)
Prev Close
€2.08
Open
€2.10
Day's High
€2.10
Day's Low
€2.05
Volume
440,791
Avg. Vol
1,330,683
52-wk High
€2.42
52-wk Low
€0.87

Latest Key Developments (Source: Significant Developments)

Pharma Mar Board Approves Deal For Sale Of Unit Zelnova Zeltia
Thursday, 23 May 2019 

May 23 (Reuters) - Pharma Mar SA ::SAYS BOARD OF DIRECTORS APPROVED SIGNING OF DEAL FOR SALE OF SHARES OF ITS SUBSIDIARY ZELNOVA ZELTIA.TOTAL CONSIDERATION TO BE PAID BY PURCHASER WILL BE 33.4 MILLION EUROS.CLOSING OF TRANSACTION IS INITIALLY EXPECTED TO TAKE PLACE ON JUNE 28, 2019.ESTIMATES DEAL WILL ENTAIL A NET CAPITAL GAIN OF ABOUT 28 MILLION euros IN PHARMA MAR'S INDIVIDUAL ACCOUNTS.UPON CLOSING OF TRANSACTION THIS WOULD ENTAIL LOSS OF ABOUT 2.5 MILLION EUROS IN GROUP'S CONSOLIDATED INCOME STATEMENT.  Full Article

Pharma Mar Q1 Net Loss Widens To 10.5 Mln Euros YoY
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::Q1 NET LOSS 10.5 MILLION EUROS VERSUS LOSS 1.3 MILLION EUROS YEAR AGO.Q1 TOTAL REVENUES 19.4 MILLION EUROS VERSUS 27.8 MILLION EUROS YEAR AGO.Q1 NEGATIVE EBITDA 7.1 MILLION EUROS VERSUS NEGATIVE 2.7 MILLION EUROS YEAR AGO.STARTS PROCESS TO DIVEST SUBSIDIARY ZELNOVA, CLASSIFIES ZELNOVA AS ‘AVAILABLE FOR SALE/DISCONTINUED OPERATIONS’.  Full Article

Pharma Mar And Luye Pharma Sign Deal For Development And Sale Of Lurbinectedin In China Territories
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::PHARMAMAR AND LUYE PHARMA <<<2186.HK>>> SIGN LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF LURBINECTEDIN IN CHINA TERRITORIES.TO RECEIVE UP-FRONT PAYMENT OF $5 MILLION .OTHER PAYMENTS WILL FOLLOW FOR REGULATORY MILESTONES AND, IN ADDITION, FOR SALES AND ROYALTIES.LUYE PHARMA TO DEVELOP LURBINECTEDIN IN SCLC IN CHINA, WHILE PHARMAMAR TO RETAIN EXCLUSIVE PRODUCTION RIGHTS FOR THE COMPOUND.  Full Article

Pharma Mar FY Net Loss Narrows To 5.5 Mln Euros YoY
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Pharma Mar SA ::FY NET LOSS 5.5 MILLION EUROS VERSUS LOSS 26.7 MILLION EUROS YEAR AGO.FY NET SALES 162.6 MILLION EUROS VERSUS 158.9 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar Receives Approval For Aplidin In Australia
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Pharma Mar SA ::AUSTRALIAN REGULATORY AGENCY (TGA) HAS APPROVED APLIDIN® TO TREAT MULTIPLE MYELOMA IN COMBINATION WITH DEXAMETHASONE.  Full Article

Pharma Mar Says Zepsyre Shows Clinical Activity In Metastatic Breast Cancer With Mutations In Brca 1/2
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Pharma Mar SA ::ZEPSYRE SHOWS SIGNIFICANT CLINICAL ACTIVITY IN METASTATIC BREAST CANCER WITH MUTATIONS IN BRCA 1/2.  Full Article

Pharma Mar 9-Month Net Result Turns To Profit Of 5.0 Mln Euros
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Pharma Mar SA ::9-MONTH NET PROFIT 5.0 MILLION EUROS VERSUS LOSS 14.5 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar's Zepsyre Gets Positive Recommendation To Continue Phase III Trial In Lung Cancer
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Pharma Mar SA ::ZEPSYRE RECEIVES POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) TO CONTINUE WITH THE PHASE III TRIAL IN SMALL-CELL LUNG CANCER.THE IDMC'S RECOMMENDATION CAME AFTER HAVING REACHED THE TARGETED NUMBER OF 600 PATIENTS RECRUITED.  Full Article

Pharma Mar Requests EU Court To Annul Refusal Of Authorization For Aplidin
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Pharma Mar SA ::APPLIES TO EUROPEAN UNION REQUESTING ANNULMENT REFUSAL OF MARKETING AUTHORIZATION FOR APLIDIN.  Full Article

AkzoNobel Acquires Xylazel in Spain
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - AKZO NOBEL NV ::REG-AKZONOBEL LEADING IN DECORATIVE PAINTS AND WOODCARE IN SPAIN WITH THE ACQUISITION OF XYLAZEL S.A..ACQUIRED XYLAZEL S.A. (XYLAZEL), A 100% SUBSIDIARY OF PHARMA MAR S.A. (PHM)..XYLAZEL HAS ABOUT 100 EMPLOYEES; REVENUE FOR 2017 TOTALED APPROXIMATELY EUR 20 MILLION..  Full Article

Spanish stocks - Factors to watch on Monday

The following Spanish stocks may be affected by newspaper reports and other factors on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: